| 1663 |
National Cancer Institute |
Html |
en |
Childhood Astrocytomas Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of childhood astrocytomas. |
| cancer treatment | 0.624127 |
| new cancer cells | 0.50571 |
| high-grade astrocytoma | 0.568902 |
| star-shaped brain cells | 0.50361 |
| metastatic brain tumors | 0.515525 |
| type | 0.567046 |
| tuberous sclerosis | 0.508341 |
| chemotherapy | 0.51254 |
| proton beam radiation | 0.504515 |
| PDQ cancer information | 0.568694 |
| clinical trial search | 0.544652 |
| brain tumors | 0.664824 |
| children | 0.509721 |
| new blood vessels | 0.577461 |
| dead tumor cells | 0.517027 |
| clinical trials | 0.906249 |
| cancer information summary | 0.537035 |
| clinical trial | 0.760659 |
| stem cell transplant | 0.512502 |
| treatment clinical trial | 0.503103 |
| radiation therapy | 0.993729 |
| Treatment Editorial Board | 0.497213 |
| beam radiation therapy | 0.519746 |
| subependymal giant cell | 0.530817 |
|
| treatment | 0.904348 |
| general information | 0.532617 |
| cancer cells | 0.898737 |
| conformal radiation therapy | 0.568043 |
| intensity-modulated radiation therapy | 0.52166 |
| specific cancer cells | 0.501338 |
| stereotactic radiation therapy | 0.544315 |
| childhood high-grade astrocytoma | 0.500502 |
| astrocytoma | 0.619975 |
| low-grade astrocytoma | 0.590271 |
| treatment clinical trials | 0.531572 |
| National Cancer Institute | 0.535683 |
| spinal cord | 0.789593 |
| effects cancer treatment | 0.512031 |
| new treatment | 0.578461 |
| external radiation therapy | 0.577741 |
| brain | 0.729014 |
| childhood astrocytoma | 0.499108 |
| cancer clinical trials | 0.564469 |
| checks tumor tissue | 0.501876 |
| tumor | 0.802924 |
| cancer | 0.956922 |
| information | 0.571652 |
| childhood low-grade astrocytoma | 0.521596 |
|
CLICK HERE |
| 1842 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de endometrio (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de endometrio. |
| Endometrial Cancer Group | 0.318951 |
| Obstet Gynecol | 0.338539 |
| papillary serous carcinoma | 0.328892 |
| uterine papillary serous | 0.337487 |
| positive peritoneal cytology | 0.310059 |
| with low-risk stage | 0.308461 |
| endometrial carcinoma | 0.512882 |
| prognostic factors | 0.307871 |
| Radiat Oncol Biol | 0.365388 |
| surgical staging | 0.309654 |
| laparoscopy versus laparotomy | 0.308759 |
| oncology group study | 0.336362 |
| endometrio estadio | 0.314607 |
| prognostic significance | 0.310042 |
| Natl Cancer Inst | 0.338736 |
| Gynecologic Oncology Group | 0.394499 |
| cancer staging | 0.313796 |
| Gynecol Oncol | 0.593302 |
| patients with | 0.367043 |
| radiation therapy | 0.313526 |
| Braquiterapia vaginal posoperatoria | 0.30677 |
| endometrial cancer | 0.978339 |
| peritoneal cytology | 0.312286 |
| stage-1 endometrial carcinoma | 0.31493 |
| cases with carcinoma | 0.307561 |
|
| Operative Radiation Therapy | 0.306859 |
| Lancet Oncol | 0.306692 |
| with endometrial carcinoma | 0.344016 |
| Danish Endometrial Cancer | 0.332392 |
| estadio iv | 0.31911 |
| estadio ii | 0.371493 |
| with surgical stage | 0.316597 |
| Cancer Staging Manual | 0.308545 |
| Féderation Internationale | 0.308609 |
| endometrial carcinoma only | 0.316396 |
| Endometrial Cancer Study | 0.319041 |
| stage i-ii papillary | 0.306581 |
| endometrial carcinoma among | 0.316625 |
| Clin Oncol | 0.320098 |
| surgical stage | 0.327711 |
| Oncol Biol Phys | 0.368458 |
| Cancer Genome Atlas | 0.314564 |
| estadio iii | 0.309959 |
| clinical stage | 0.315784 |
| cuello uterino | 0.329408 |
| Gynecol Cancer | 0.309855 |
| vaginal brachytherapy | 0.308102 |
| treated with | 0.309769 |
| with or without | 0.308543 |
|
CLICK HERE |
| 1888 |
National Cancer Institute |
Html |
es |
Tratamiento del linfoma de Hodgkin en adultos (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del linfoma de Hodgkin en adultos. |
| siguientes procedimientos | 0.457132 |
| células madre | 0.773484 |
| sedimentación globular vsg | 0.343223 |
| estadio iv | 0.386067 |
| siguientes elementos | 0.335371 |
| sudores nocturnos | 0.52867 |
| Elabora glóbulos | 0.342317 |
| siguientes afecciones | 0.326701 |
| siguientes especialistas | 0.324883 |
| siguientes tipos | 0.334479 |
| área cercanos.ampliar linfoma | 0.414688 |
| rayos x | 0.318853 |
| Hodgkin Lymphoma | 0.444389 |
| abdomen).ampliar linfoma | 0.405698 |
| enlace drugs approved | 0.376199 |
| largo plazo | 0.313634 |
| malformaciones congénitas | 0.344911 |
| escáner tep | 0.32264 |
| ondas sonoras | 0.318768 |
| estadio ie | 0.448154 |
| efectos tardÃos | 0.386184 |
| cáncer.ampliar aspiración | 0.320544 |
|
| quimioterapia sistémica | 0.399855 |
| National Cancer Institute | 0.315084 |
| siguientes riesgos | 0.314848 |
| Instituto Nacional | 0.326237 |
| PDQ Tratamiento | 0.422426 |
| estadio iie | 0.390253 |
| lÃquido incoloro | 0.32327 |
| Herpes zóster | 0.316049 |
| estadio iiie | 0.444346 |
| siguientes problemas | 0.333894 |
| estadio e | 0.345757 |
| siguientes factores | 0.326864 |
| Physician Data Query | 0.353006 |
| siguientes subtipos | 0.336371 |
| siguientes sitios | 0.33013 |
| Leucemia mielógena aguda | 0.327537 |
| hodgkin clásico.ampliar célula | 0.434672 |
| estadio iiis | 0.943901 |
| células formadoras | 0.331979 |
| almacena glóbulos | 0.343421 |
| siguientes sumarios | 0.346893 |
| siguientes pruebas | 0.333482 |
|
CLICK HERE |
| 1923 |
National Cancer Institute |
Html |
es |
Tratamiento del melanoma (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del melanoma. |
| almacena agua | 0.234953 |
| siguientes procedimientos | 0.33648 |
| estadio iv | 0.436307 |
| siguientes aspectos | 0.242705 |
| CTLA-4.Ampliar Inhibidor | 0.229258 |
| genes braf | 0.219515 |
| pequeña cantidad | 0.22974 |
| siguientes tipos | 0.26039 |
| estadios ia | 0.227409 |
| ganglio linfático centinela | 0.971469 |
| rayos x | 0.230817 |
| estadio ib | 0.421722 |
| estadio ia | 0.418874 |
| enlace drugs approved | 0.315654 |
| células t | 0.340582 |
| luz solar | 0.830082 |
| PD-1.Ampliar Inhibidor | 0.228522 |
| vitamina d | 0.235166 |
|
| National Cancer Institute | 0.217987 |
| lunar atÃpico | 0.239383 |
| Instituto Nacional | 0.232974 |
| estadios iia | 0.230643 |
| PDQ Tratamiento | 0.658062 |
| melanoma causa efectos | 0.315066 |
| antecedentes familiares | 0.293778 |
| cabo pruebas | 0.278327 |
| estadio iia | 0.421244 |
| estadio iic | 0.418402 |
| PDQ Exámenes | 0.269726 |
| Physician Data Query | 0.266129 |
| lápiz mide | 0.244567 |
| estadio iii | 0.594614 |
| siguientes situaciones | 0.233677 |
| panel derecho | 0.258009 |
| siguientes pruebas | 0.238893 |
| melanoma ocular uveal | 0.435674 |
|
CLICK HERE |
| 1929 |
National Cancer Institute |
Html |
es |
Tratamiento del carcinoma de sitio primario desconocido (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer metastásico que se diseminó desde un sitio primario desconocido. |
| PDQ Tratamiento | 0.503744 |
| siguientes procedimientos | 0.523984 |
| alta potencia | 0.503524 |
| siguientes elementos | 0.505673 |
| siguientes aspectos | 0.504431 |
| Physician Data Query | 0.507109 |
| coriónica humana beta | 0.506354 |
| radioterapia externa causa | 0.507986 |
| tumor primario oculto.Ampliar | 0.520296 |
| siguientes razones | 0.505928 |
| siguientes tipos | 0.504856 |
|
| vÃa oral | 0.502538 |
| rayos x | 0.503516 |
| sitio primario desconocido | 0.964151 |
| Sudores nocturnos | 0.504661 |
| cuáles pruebas | 0.503677 |
| numerosos ensayos | 0.506292 |
| National Cancer Institute | 0.501623 |
| siguientes riesgos | 0.501356 |
| células cancerosas ayuda | 0.516934 |
| Instituto Nacional | 0.503286 |
|
CLICK HERE |
| 1980 |
National Cancer Institute |
Html |
es |
Tratamiento del sarcoma de Ewing (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de los tumores de la familia del sarcoma de Ewing. |
| Cirujano oncólogo | 0.631512 |
| siguientes procedimientos | 0.653106 |
| células madre | 0.978655 |
| adultos jóvenes | 0.637237 |
| faja ajustadora | 0.638641 |
| vÃa oral | 0.627826 |
| rayos x | 0.63487 |
| estudio tipos | 0.620537 |
| enlace drugs approved | 0.646857 |
| niño ayuda | 0.64117 |
| células t | 0.686984 |
| efectos tardÃos | 0.851996 |
| PDQ Efectos tardÃos | 0.679663 |
| Ewing extraóseo | 0.77445 |
| National Cancer Institute | 0.625093 |
| IRMN).Ampliar Imágenes | 0.631059 |
|
| encontrarlo.ampliar exploración | 0.638439 |
| ortopedista oncólogo | 0.633744 |
| Instituto Nacional | 0.644246 |
| PDQ Tratamiento | 0.658351 |
| determinados cambios | 0.617816 |
| Ewing causa efectos | 0.748473 |
| presente sección | 0.621848 |
| explorador tep | 0.641296 |
| nuevos tipos | 0.626452 |
| Physician Data Query | 0.690644 |
| Soft Tissue Sarcoma | 0.727359 |
| diseminó.ampliar aspiración | 0.638694 |
| quimioterapia sistémica forma | 0.678849 |
| leucemia mieloide aguda | 0.649605 |
| tumor óseo | 0.67804 |
| siguientes pruebas | 0.708113 |
|
CLICK HERE |
| 2003 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores de estroma gastrointestinal (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los tumores de estroma gastrointestinal |
| Corless CL | 0.538141 |
| Gastric stromal sarcoma | 0.50605 |
| stromal tumors irrespective | 0.50378 |
| Gastrointestinal pacemaker | 0.510002 |
| cases with | 0.505031 |
| Demetri GD | 0.510561 |
| antÃgeno cd117 | 0.5043 |
| stromal tumors but | 0.503793 |
| Sin embargo | 0.508884 |
| KIT-negative gastrointestinal | 0.505275 |
| gastrointestinal stromal sarcomas | 0.507782 |
| gen kit | 0.50569 |
| Cancer Res | 0.504191 |
| sclerosing stromal tumors | 0.504057 |
| receptor kit | 0.508691 |
| with mutational analysis | 0.504267 |
| stromal tumor patient | 0.504863 |
| Multiple gastrointestinal | 0.505317 |
| before imatinib with | 0.505687 |
| PDGFRA activating mutations | 0.504562 |
| Oncol Rep | 0.503948 |
| nervioso autónomo gastrointestinal | 0.506079 |
| interstitial cells | 0.505694 |
| TEGI primario recién | 0.504948 |
| new cases with | 0.504631 |
|
| verdadero tegi | 0.504221 |
| stromal tumor occurs | 0.504698 |
| gastric stromal tumours | 0.506473 |
| microscopic gastrointestinal | 0.505987 |
| gastrointestinal tract | 0.505493 |
| gastrointestinal stromal tumors | 0.979159 |
| Surg Pathol | 0.538619 |
| Duensing A | 0.505663 |
| tumors have unique | 0.505149 |
| molecular genetic study | 0.50922 |
| Cancer Staging Manual | 0.525628 |
| tirosina cinasa kit | 0.507752 |
| tirosina cinasa | 0.607449 |
| proteÃna cinasa | 0.508725 |
| Heinrich MC | 0.512562 |
| carney triad | 0.506455 |
| gastrointestinal stromal tumours | 0.529292 |
| with long-term follow-up | 0.503857 |
| stromal sarcoma | 0.507115 |
| metastatic gastrointestinal | 0.505468 |
| NF1-associated gastrointestinal | 0.509992 |
| ANNUAL REVIEWS | 0.505692 |
| pacemaker cell tumor | 0.506911 |
| AJCC Cancer Staging | 0.518324 |
|
CLICK HERE |
| 2014 |
National Cancer Institute |
Html |
es |
Aspectos generales de los exámenes de detección del cáncer (PDQ®)–Versión para profesionales de salud |
Información sobre la medición de la eficacia de las pruebas de detección del cáncer y la evaluación de la solidez de las pruebas obtenidas en estudios de investigación de detección del cáncer. |
| Does screening | 0.616458 |
| importancia clÃnica | 0.620073 |
| muertes prematuras | 0.612815 |
| American Cancer Society | 0.649437 |
| Woods WG | 0.609081 |
| shared decision-making | 0.610684 |
| únicos exámenes | 0.617228 |
| Malmo mammographic screening | 0.618339 |
| case-control studies | 0.618658 |
| Instituto Nacional | 0.618095 |
| SEER Program | 0.61206 |
| examen tisular | 0.612004 |
| patient decision aids | 0.642735 |
| Estados Unidos | 0.671925 |
| Clin Epidemiol | 0.61257 |
| Natl Cancer Inst | 0.655145 |
| screening with | 0.61747 |
| screening efficacy | 0.629033 |
| cancer screening | 0.803421 |
| Kramer BS | 0.609339 |
| estadio iv | 0.624173 |
| Cancer Intervention | 0.613844 |
| End Results | 0.611945 |
| Evaluating new screening | 0.618163 |
| voluntarios sanos | 0.610696 |
|
| Decision Aid Standards | 0.609164 |
| sobrediagnóstico resultante | 0.608646 |
| diagnosed with | 0.611303 |
| decision aid | 0.652528 |
| Cancer Facts | 0.614043 |
| Day NE | 0.608989 |
| datos probatorios indirectos | 0.611287 |
| evaluating neuroblastoma screening | 0.619704 |
| Welch HG | 0.609007 |
| mammography screening | 0.616883 |
| cancer screening strategies | 0.649219 |
| Intern Med | 0.611038 |
| breast cancer screening | 0.675789 |
| Clin Oncol | 0.611547 |
| Cancer screening among | 0.630365 |
| systematic review | 0.61189 |
| cáncer surveillance | 0.636085 |
| Mass screening | 0.616536 |
| cuello uterino | 0.611009 |
| Neuroblastoma Screening Project | 0.622021 |
| datos probatorios | 0.981275 |
| Black WC | 0.609219 |
| mejores desenlaces | 0.609922 |
| Cancer Screening Trial | 0.636288 |
|
CLICK HERE |
| 15637 |
National Cancer Institute |
Html |
null |
Research Funding Mechanisms |
The NCI uses grants, cooperative agreements, and contracts to help stimulate and fund cancer research. |
|
|
CLICK HERE |
| 16257 |
National Cancer Institute |
Html |
es |
Prevención |
La investigación del NCI de prevención va desde identificación de factores ambientales y de estilos de vida que influyen en el riesgo de cáncer hasta la biología de la formación del cáncer y la evaluación para diseminar intervenciones de prevención. |
| próxima generación | 0.432035 |
| Mejor reducción | 0.436692 |
| Investigación Nacional Colaborativa | 0.455747 |
| Investigación Oncológica | 0.43883 |
| Nuevos planteamientos | 0.440499 |
| investigación sustancias | 0.43567 |
| Estudio Vida Familiar | 0.45233 |
| Estados Unidos | 0.908876 |
| numerosos factores | 0.443836 |
| cabo estudios | 0.446295 |
| Cáncer apoya programas | 0.610288 |
|
| cánceres más | 0.43473 |
| numerosos estudios | 0.443241 |
| posibles terapias | 0.437443 |
| Pre-Cancer Atlas | 0.437082 |
| el uso | 0.430938 |
| inmensa complejidad | 0.437794 |
| amplio rango | 0.43275 |
| prevención del cáncer del nci | 0.509541 |
| creación de vacunas | 0.467866 |
| prueba formas | 0.434098 |
| Estados Unidos gastarán | 0.466237 |
|
CLICK HERE |